Eric Carlson, an associate in Goodwin’s Private Equity group, represents private equity and venture capital firms, investors and private companies in a broad range of strategic transactions. His practice focuses on private equity, venture capital, mergers and acquisitions and general corporate representation. Mr. Carlson is also a member of the firm's Impact and Responsible Investing Practice.

Prior to joining Goodwin, Mr. Carlson was an associate in the Boston office of Locke Lord.

In law school, Mr. Carlson was an articles editor for the Transnational Law Review.

Areas of Practice
Domaines D’Expertise





Mr. Carlson’s work for clients has included representing and/or advising:

  • The sale of Innovative Food Processors, Inc., an Ampersand Capital Partners portfolio company, to Balchem Corporation.
  • The sale of Dynex Technologies, Inc., an Ampersand Capital Partners portfolio company, to Telegraph Hill Partners.
  • The sale of Agilux Laboratories, Inc., an Ampersand Capital Partners portfolio company, to Charles River Laboratories International, Inc.
  • Florida Biologix in its merger with Brammer Biopharmaceuticals LLC, forming Brammer Bio, LLC, a cell and gene therapy biologics contract development and manufacturing organization.
  • Avista Pharma in its acquisition of the GMP contract manufacturing, development and animal health services business of Scynexis, Inc. (NASDAQ: SCYX).*
  • Nitinol Devices and Components, Inc. (“NDC”) in its acquisition of Interface Catheter Solutions (“Interface”). NDC is the largest contract manufacturer of nitinol-based medical devices and Interface is a pioneer is medical balloon technology and the leading contract manufacturer of balloon catheter systems. Following the acquisition, NDC and Interface created Confluent Medical Technologies, a leading contract manufacturer of specialized medical devices.*
  • Ampersand Capital Partners in its acquisition of Protein Technologies, a maker of peptide synthesizers and reagents.*
  • Accuratus Lab Services, an Ampersand Capital Partners portfolio company, in its acquisition of certain assets related to the chemistry, manufacturing and control testing services business of Array BioPharma Inc.*
  • Gelesis, a medical product developer focused on treating weight loss and obesity, in a growth equity financing.  Gelesis is a portfolio company of PureTech Ventures.
  • Tal Medical, a clinical stage medical device company focused on neurostimulation and treatment for psychiatric disorders, in a growth equity financing.  Tal Medical is a portfolio company of PureTech Ventures.
  • Novartis Venture Fund in its investment in Macrolide Pharmaceuticals, an anti-infective company focused on the synthesis of antibiotics.*
  • Ampersand Capital Partners in its minority investment in CutisPharma, an industry leader in prescription compounding pharmaceuticals.*
  • CRI Lifetree, a clinical research service provider, in its acquisition by clinical research organization PRA Health Sciences, a KKR portfolio company.*
  • Nautic Partners in its acquisition of Custom Windows, a leading designer and manufacturer of impact resistant and non-impact windows.*
  • GnuBio Inc., a developer of fully integrated droplet-based DNA sequencing technology, as general counsel and in its acquisition by Bio-Rad Laboratories, Inc.*
  • Boston Dynamics, an advanced robotics development company, in its acquisition by Google, Inc.
  • Ampersand Capital Partners in the sale of CoreLab Partners and take-private of Bioclinica, both global clinical trial solutions businesses.*
  • Stemline Therapeutics, Inc. in its initial public offering.*
  • Modified Polymer Components in its acquisition of Biomedical Structures, LLC.*
  • Magellan Diagnostics in its strategic spin-off of Dynex Technologies, Inc.*
  • Magellan Diagnostics in the sale of its microbiology testing products division, TREK Diagnostic Systems, to Thermo Fischer Scientific.*

*Denotes experience prior to joining Goodwin.

In The News









J.D., 2009
Suffolk University School of Law

(magna cum laude)

B.S., 2002
Babson College

(magna cum laude)



Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique